| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/06/2005 | CN1195756C Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands |
| 04/06/2005 | CN1195755C Pyrrolo [2, 3-d] pyrimidine compounds |
| 04/06/2005 | CN1195741C Pyrimidinone compounds, pharmaceutical compositions containing the compounds and the process for preparing the same |
| 04/06/2005 | CN1195740C Pharmaceutical compositions comprising 2-quinolones |
| 04/06/2005 | CN1195738C 2'-substd. 1, 1'-biphenyl-2-carbonamides, method for production thereof, use thereof as medicament and pharmaceutical preparation contg. said compounds |
| 04/06/2005 | CN1195737C HIV proteinase inhibitor |
| 04/06/2005 | CN1195736C Gatrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| 04/06/2005 | CN1195735C Sulfonylamino derivatives which inhibit matrix-degrading metallopr teinases |
| 04/06/2005 | CN1195547C Preventives / remedies for glaucoma |
| 04/06/2005 | CN1195536C Superfine gastrodia tuber and American ginseng superfine powder buccal lozenge |
| 04/06/2005 | CN1195534C Physiologically active compositions of basidiomycotina and araliaceae extracts |
| 04/06/2005 | CN1195524C Use of benzenesulfonyl (thio) ureas in combination with beta-receptor retarder for treatment and prophylaxis of dysfunctions of autonomous nervous system |
| 04/06/2005 | CN1195522C Benzodiazepine derivatives |
| 04/06/2005 | CN1195521C Use of quinazoline compounds for the treatment of polycystic kidney disease |
| 04/06/2005 | CN1195515C Amide derivatives for antiangiogenic and/or antitumorgenic use |
| 04/06/2005 | CN1195513C Tocopherols, tocotrienols, other chroman and side chain derivatives and uses |
| 04/06/2005 | CN1195502C Periadventitial delivery device |
| 04/06/2005 | CN1195497C Biodegradable polymer encapsulated 5-hydroxytryptamine receptor antagonist and method for preparing the same |
| 04/06/2005 | CN1195494C Oral liquid mucoadhesive compositions |
| 04/06/2005 | CN1195488C Method for scavenging free radical by orange extracted liquor |
| 04/05/2005 | US6875886 Modified PSMA ligands and uses related thereto |
| 04/05/2005 | US6875868 Pteridine compounds for the treatment of psoriasis |
| 04/05/2005 | US6875867 Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors |
| 04/05/2005 | US6875846 Heterologous polypeptide of the TNF family |
| 04/05/2005 | US6875845 Polypeptide for use in the treatment of cancer |
| 04/05/2005 | US6875791 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| 04/05/2005 | US6875790 Viricides |
| 04/05/2005 | US6875789 Pyrazole-derived kinase inhibitors and uses thereof |
| 04/05/2005 | US6875780 Compounds that modulate PPAR activity and methods for their preparation |
| 04/05/2005 | US6875779 Cyclooxygenase inhibitor |
| 04/05/2005 | US6875775 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 04/05/2005 | US6875770 Antiinflamamtory agents; side effect reduction |
| 04/05/2005 | US6875767 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors |
| 04/05/2005 | US6875765 Inhibitors of interleukin-1 beta converting enzyme and other cysteine proteases in the ICE family |
| 04/05/2005 | US6875757 LPA receptor agonists and antagonists and methods of use |
| 04/05/2005 | US6875750 Methylation of target compound using methyltransferase |
| 04/05/2005 | US6875749 Methods of facilitating vascular growth |
| 04/05/2005 | US6875741 Insulin and IGF-1 receptor agonists and antagonists |
| 04/05/2005 | US6875736 Methods for identifying RNA binding compounds |
| 04/05/2005 | US6875597 Comprises nucleotide sequences coding sulfotransferase for identifying modulators and designing drug delivery systems |
| 04/05/2005 | US6875576 Detection of modulators of receptor binding activity; obtain sample containing receptor, incubate with modulator, monitor adjustment of binding activity of receptor |
| 04/05/2005 | US6875570 Proteins and nucleic acids encoding same |
| 04/05/2005 | US6875446 Method for prophylaxis and/or treatment of thromboembolism |
| 04/05/2005 | US6875430 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 04/05/2005 | US6875428 Especially endcapped polyethylene glycols, polypropylene glycols or copolymers of them |
| 04/05/2005 | US6875419 Paramagnetic metal ion-based macrocyclic magnetization transfer contrast agents and method of use |
| 04/05/2005 | CA2276146C Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| 04/05/2005 | CA2270086C New benzothiophene, benzofuranic and indolic derivatives, their preparation process and pharmaceutical compositions containing them |
| 04/05/2005 | CA2235138C Reverse-turn mimetics and methods relating thereto |
| 04/05/2005 | CA2166975C Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
| 04/05/2005 | CA2141209C Novel pyridyl- and pyrimidylpiperazine derivatives |
| 04/05/2005 | CA1341478C Therapeutic methods using catalytic antibodies |
| 03/31/2005 | WO2005028464A1 Endurance improving agent |
| 03/31/2005 | WO2005028463A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | WO2005028455A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 03/31/2005 | WO2005028453A1 Phenylacetic acid derivative, process for producing the same, and use |
| 03/31/2005 | WO2005028441A1 Cinnamoyl derivatives and use thereof |
| 03/31/2005 | WO2005028440A1 Novel gamma secretase inhibitors |
| 03/31/2005 | WO2005028439A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | WO2005028438A1 Novel piperidine derivative |
| 03/31/2005 | WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 03/31/2005 | WO2005027969A1 Remedy for eye diseases accompanied by optic nerve injuries |
| 03/31/2005 | WO2005027968A1 Remedy for down syndrome |
| 03/31/2005 | WO2005027934A1 Prolyl oligopeptidase inhibitor |
| 03/31/2005 | WO2005027907A1 Use of chk1 inhibitors to control cell proliferation |
| 03/31/2005 | WO2005027905A1 Pharmaceutical compositions for the treatment of organophosphate poisoning |
| 03/31/2005 | WO2005027903A1 Polyether brevetoxin derivatives as a treatment for neurotoxic shellfish poisoning and ciguatera fish poisoning |
| 03/31/2005 | WO2005027898A1 Amino acid compositions |
| 03/31/2005 | WO2005027896A1 Concurrent drugs |
| 03/31/2005 | WO2005027893A1 HUMAN β-DEFENSIN SECRETION PROMOTER |
| 03/31/2005 | WO2005027831A2 Modulators of p-selectin glycoprotein ligand 1 |
| 03/31/2005 | WO2005009947A3 Aryl heteroaromatic products, compositions comprising the same and use thereof |
| 03/31/2005 | WO2004108141A3 Bach-o-protein coupled receptor releated methods |
| 03/31/2005 | WO2004108133A3 Modulators of vr1 receptor |
| 03/31/2005 | WO2004096276A9 Sugar intake-ability enhancer |
| 03/31/2005 | WO2003073987A3 Compounds that modulate the activity of ptp-1b and tc-ptp |
| 03/31/2005 | WO2003018756A3 Methods for preparing purified prostaglandin e synthase |
| 03/31/2005 | WO2002099054A3 Hccss as modifiers of the p53 pathway and methods of use |
| 03/31/2005 | WO2002042319A9 2-substituted estrogens as antiangiogenic agents |
| 03/31/2005 | US20050071894 Nonhuman model animal lacking the ability to control lymphocyte migration |
| 03/31/2005 | US20050070720 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 03/31/2005 | US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents |
| 03/31/2005 | US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease |
| 03/31/2005 | US20050070706 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders |
| 03/31/2005 | US20050070606 Pharmaceutical agent for mitochondrial disorders |
| 03/31/2005 | US20050070605 Reacting an organophosphouus compound with metallized alkane; forming atorvastatin, lorastatin, pitavastatin, fluvastatin |
| 03/31/2005 | US20050070595 Complex of trioxane with iron compound |
| 03/31/2005 | US20050070591 Indole derivative |
| 03/31/2005 | US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity |
| 03/31/2005 | US20050070582 For example,1-{[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl}-4-ethylpiperazine or 1-{[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl}piperazine; for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders |
| 03/31/2005 | US20050070574 Novel compounds |
| 03/31/2005 | US20050070572 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies |
| 03/31/2005 | US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors |
| 03/31/2005 | US20050070568 Therapeutic acridone and acridine compounds |
| 03/31/2005 | US20050070566 Imidazoquinoline derivatives |
| 03/31/2005 | US20050070561 For example, 2-(3-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino}-1H-pyrazol-5-yl)-N-phenylacetamide; use in the treatment of certain diseases, in particular to proliferative disease such as cancer |
| 03/31/2005 | US20050070559 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |
| 03/31/2005 | US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions |
| 03/31/2005 | US20050070557 Use of pyrazolo(4,3-d)pyrimidine derivatives; for example, 5-(3-chloro-benzyl)-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one |